

Pharmacy Drug Policy Checklist

POLICY NAME Xolremdi (mavorixafor) POLICY # 2773P

Criteria

Coverage Criteria	
	Diagnosis of WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome confirmed by pathogenic and or likely pathogenic variants in the CXCR4 gene
	Documentation of symptoms and complications associated with WHIM syndrome (e.g. warts, hypogammaglobulinemia, recurrent infections, and myelokathexis)
	Documentation of member's baseline absolute lymphocyte count (ALC) and number of infections experienced within the last year
	Age 12 years or older
	Prescribed by or in consultation with an immunologist, geneticist, or hematologist
	Baseline absolute neutrophil count (ANC) is $\leq 400 \text{ cells}/\mu\text{L}$
	Review of clinical documentation and confirming that patient has met all of the above requirements for treatment completed by both a pharmacist and medical director